BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

657 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-11-30

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open label, multi-centre, non-interventional post-marketing surveillance

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )

NCT01381393

Osteoporosis

COMPLETED

Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis

NCT02271204

Osteoporosis

COMPLETED

A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.

NCT00545207

Post-Menopausal Osteopenia

COMPLETED PHASE3

A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia

NCT02604836

Postmenopausal Osteoporosis

COMPLETED PHASE4

A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia

NCT00129623

Post-Menopausal Osteopenia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety of Ibandronate injection administered in postmenopausal osteoporosis patients according to the prescribing information

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BONVIVA(ibandronate)

Patients administrated ibandronate injection with postmenopausal osteoporosis

BONVIVA(ibandronate) injection

Intervention Type DRUG

Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BONVIVA(ibandronate) injection

Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All subjects must satisfy the following criteria at study entry:

Subjects administered with BONVIVA(ibandronate) injection following the locally approved prescribing information Women diagnosed with postmenopausal osteoporosis. Subjects who the investigator believes that they can and will comply with the requirements of the protocol Subjects with no experience of treatment using ibandronate injection Note: Subjects, who have experience of other bisphosphonates treatment, can be included.

Subjects who are indicated and administered of ibandronate injection according to the Prescribing Information in normal prescription use

Exclusion Criteria

The following criteria should be checked at the time of study entry.

According to contraindication on the prescribing information, ibandronate injection should not be administered to the following patients:

Patients with known hypersensitivity to ibandronate injection or to any of its excipients Uncorrected hypocalcemia Note: Ibandronate injection is not recommended for use in patients who have a serum creatinine above 200 μmol/l (2.3 mg/dl) or who have a creatinine clearance (measured or estimated) below 30 ml/min, because of limited clinical data available from studies including such patients.

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No